ArticleCancer immunology, immunotherapy : CII2007
Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma.
Article in Cancer immunology, immunotherapy : CII, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 59 citations in OpenAlex.
- Canine cutaneous and subcutaneous soft tissue sarcoma in dogs: a consensus report from the Brazilian association of veterinary oncology.Frontiers in veterinary science · 2026Review
- Design, synthesis, and evaluation of A therapeutic vaccine candidate against lung cancer based on multi-epitopes of MAGE-A3, TGF-β2, and VEGF-A.BMC cancer · 2025Article
- Vascular endothelial growth factor concentrations in the cerebrospinal fluid of dogs with neoplastic or inflammatory central nervous system disorders.Journal of veterinary internal medicine · 2021Article
- Induction of humoral immune responses and inhibition of metastasis in mice by a VEGF peptide-based vaccine.Iranian journal of basic medical sciences · 2020Article
- Canine Cancer: Strategies in Experimental Therapeutics.Frontiers in oncology · 2019Review
- EGFR may participate in immune evasion through regulation of B7‑H5 expression in non‑small cell lung carcinoma.Molecular medicine reports · 2018Article
- Canine sarcomas as a surrogate for the human disease.Pharmacology & therapeutics · 2018Review
- Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.The oncologist · 2018Review
- Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models.Cancer immunology, immunotherapy : CII · 2017Article
- Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Oncolytic virotherapy of canine and feline cancer.Viruses · 2014Review
- Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy.PloS one · 2014Article
- Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.PloS one · 2012Article
- Anti-angiogenesis immunotherapy.Human vaccines · 2011Article
- A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Anti-angiogenic active immunotherapy: a new approach to cancer treatment.Cancer immunology, immunotherapy : CII · 2008Review
- NIAID resources for developing new therapies for severe viral infections.Antiviral research · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Active immunization against pro-angiogenic growth factors or their receptors is an emerging strategy for controlling tumor growth and angiogenesis. Previous studies in rodent tumor models have indicated that immunization against xenogeneic growth factors is more likely to induce effective anti-tumor responses than immunization against the autologous growth factor. However, the effectiveness or safety of the xenogeneic vaccination approach has not been previously assessed in a clinically relevant outbred, spontaneous tumor model. Therefore, we investigated the safety and anti-tumor and anti-angiogenic effects of a xenogeneic vascular endothelial cell growth factor (VEGF) vaccine in pet dogs with spontaneous cancer. Nine dogs with soft tissue sarcoma were immunized with a recombinant human VEGF vaccine over a 16-week period. The effects of immunization on antibodies to human and canine VEGF, circulating VEGF concentrations, tumor microvessel density (MVD), and tumor growth were assessed. The xenogeneic VEGF vaccine was well-tolerated by all dogs and resulted in induction of humoral responses against both human and canine VEGF in animals that remained in the study long enough to receive multiple immunizations. Three of five multiply immunized dogs also experienced sustained decreases in circulating plasma VEGF concentrations and two dogs had a significant decrease in tumor MVD. The overall tumor response rate was 30% for all treated dogs in the study. We conclude therefore that a xenogeneic VEGF vaccine may be a safe and effective alternative means of controlling tumor growth and angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.